Children With Cystic Fibrosis Are Infected With Multiple Subpopulations of Mycobacterium abscessus With Different Antimicrobial Resistance Profiles. by Shaw, Liam P et al.
Shaw, Liam P; Doyle, Ronan M; Kavaliunaite, Ema; Spencer, Helen;
Balloux, Francois; Dixon, Garth; Harris, Kathryn A (2019) Children
with cystic fibrosis are infected with multiple subpopulations of My-
cobacterium abscessus with different antimicrobial resistance profiles.
Clinical infectious diseases. ISSN 1058-4838 DOI: https://doi.org/10.1093/cid/ciz069
Downloaded from: http://researchonline.lshtm.ac.uk/4652530/
DOI: 10.1093/cid/ciz069
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
M A J O R  A R T I C L E
M. abscessus Subclones in CF patients • cid  :XX (XX XXXX) • 1
Clinical Infectious Diseases
 
Received 8 October 2018; editorial decision 6 December 2018; accepted 21 January 2019; 
published online January 26, 2019.
Correspondence: K. A. Harris Department of Microbiology, Virology and Infection Control, 
Great Ormond Street Hospital NHS Foundation Trust, London WC1N 3JH, UK (kathryn.harris@
gosh.nhs.uk).
Clinical Infectious Diseases®  2019;XX(XX):1–9
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society 
of America. This is an Open Access article distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted 
reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
DOI: 10.1093/cid/ciz069
Children With Cystic Fibrosis Are Infected With Multiple 
Subpopulations of Mycobacterium abscessus With Different 
Antimicrobial Resistance Profiles
Liam P. Shaw,1,2,  Ronan M. Doyle,3,4,  Ema Kavaliunaite,5 Helen Spencer,5 Francois Balloux,1,  Garth Dixon,3,4 and Kathryn A. Harris3,4
1UCL Genetics Institute, University College London, London, 2Nuffield Department of Medicine, John Radcliffe Hospital, Oxford, 3Department of Microbiology, Virology and Infection 
Control, 4National Institute for Health Research Biomedical Research Centre, and 5Paediatric Respiratory Medicine and Lung Transplantation, Great Ormond Street Hospital National Health 
Services Foundation Trust, London, United Kingdom
Background. Children with cystic fibrosis (CF) can develop life-threatening infections of Mycobacterium abscessus. These pre-
sent a significant clinical challenge, particularly when the strains involved are resistant to antibiotics. Recent evidence of with-
in-patient subclones of M. abscessus in adults with CF suggests the possibility that within-patient diversity may be relevant for the 
treatment of pediatric CF patients.
Methods. We performed whole-genome sequencing (WGS) on 32 isolates of M. abscessus that were taken from multiple body 
sites of 2 patients with CF who were undergoing treatment at Great Ormond Street Hospital, United Kingdom, in 2015.
Results. We found evidence of extensive diversity within patients over time. A clustering analysis of single nucleotide variants 
revealed that each patient harbored multiple subpopulations, which were differentially abundant between sputum, lung samples, 
chest wounds, and pleural fluid. The sputum isolates did not reflect the overall within-patient diversity and did not allow for the de-
tection of subclones with mutations previously associated with macrolide resistance (rrl 2058/2059). Some variants were present at 
intermediate frequencies before the lung transplants. The time of the transplants coincided with extensive variation, suggesting that 
this event is particularly disruptive for the microbial community, but the transplants did not clear the M. abscessus infections and 
both patients died as a result of these infections.
Conclusions. Isolates of M. abscessus from sputum do not always reflect the entire diversity present within the patient, which 
can include subclones with differing antimicrobial resistance profiles. An awareness of this phenotypic variability, with the sampling 
of multiple body sites in conjunction with WGS, may be necessary to ensure the best treatment for this vulnerable patient group.
Keywords. lung transplant; whole-genome sequencing; within-patient diversity; macrolides; physiological niches.
Mycobacterium abscessus is a nontuberculous mycobacteria that 
has recently emerged as a major pathogen in cystic fibrosis (CF) 
patients [1]. Infection with M. abscessus is associated with poor 
clinical outcomes, particularly in conjunction with lung trans-
plantation [2]. Treatment is challenging, due to the intrinsic 
resistance of M.  abscessus to many classes of antibiotics [3], 
along with certain genotypes that drastically alter the efficacy 
of antibiotics [4]. The antimicrobial resistance (AMR) profile of 
isolates is highly relevant for treatment, but current diagnostic 
work mainly uses isolates from sputum, which may not reflect 
the full range of genetic diversity within the patient and, there-
fore, may fail to recover the true AMR profile.
Minority variants from whole-genome sequencing (WGS) 
have been used to infer the presence of multiple subpopulations 
(subclones) in longitudinal sputum isolates of M. abscessus [5]. 
However, whether patients harbor further unsampled genetic 
diversity remains an open question. The lung is known to be 
capable of harboring considerable pathogen diversity in chronic 
infections. For example, Mycobacterium tuberculosis infections 
exist as multiple subpopulations with different AMR profiles [6, 
7]. The potential relevance of this genetic diversity for treatment 
is not yet known.
For this reason, we investigated longitudinal isolates from 2 
patients infected with M.  abscessus subsp. abscessus  who were 
undergoing lung transplants at Great Ormond Street Hospital 
(Figure 1) and identified variable genomic positions within 
samples (single nucleotide variants [SNVs]). By including iso-
lates not only from sputum samples, but also biologically im-
portant compartments such as pleural fluid, lung tissue, and 
swabs from chest wounds, we aimed to establish the extent and 
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significance of the within-patient variation in M. abscessus for 
this vulnerable group.
METHODS
Patient Cohort and Sample Collection
Great Ormond Street Hospital is a large, regional center for pe-
diatric CF patients and is the largest pediatric lung transplant 
center in the United Kingdom. The 2 patients in this study 
(Patient 1 and Patient 2) were from other CF centers and were 
seen at Great Ormond Street Hospital for a transplant assess-
ment, during the lung transplant procedure, and posttransplant 
(Table 1). Both patients in this study underwent regular res-
piratory microbiological diagnostic investigations, including 
specific stains and cultures for mycobacteria on sputum pre-
transplant and posttransplant and for explanted lung tissue, 
bronchoalveolar lavage, pleural fluid, and clamshell incision 
Figure 1. Overview of the sampling scheme and antibiotic treatment. The treatment regimes included intravenous antibiotics (boxed colored lines) and oral antibiotics 
(faint colored lines) for both patients during the 6-month period prior to their lung transplant (red vertical line). The sampling scheme is represented at the bottom of each 
panel (colored points). Abbreviations: BAL, bronchoalveolar lavage; IV, intravenous; PEG, percutaneous endoscopic gastrostomy.
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wound swabs posttransplant. All further microbiological inves-
tigations were carried out on “sweeps” from pure culture plates. 
All M. abscessus isolates cultured in our laboratory are identi-
fied to the subspecies level by polymerase chain reaction (PCR) 
amplification and sequencing of the hsp65 and rpoB genes, 
and by inducible macrolide resistance predicted by PCR am-
plification and sequencing of the erm(41) gene, as previously 
described [8]. Variable nucleotide tandem repeat (VNTR) pro-
files were obtained for selected isolates, as previously described 
[9]. Phenotypic sensitivity data was obtained from the myco-
bacterial reference laboratory (Table 3).
Demographic and clinical data were extracted from the 
Patient Administration System and microbiological data 
from the Laboratory Information Management system 
(OMNI-client ISS) using structured query language data-
bases and Excel spreadsheets. Additional sources of informa-
tion included CF and transplantation databases. Details of the 
antimicrobial therapies administered prior to transplantation 
were provided by the referring CF centers. All investigations 
were performed in accordance with the Hospitals Research 
governance policies and procedures.
Whole-genome Sequencing
DNA extraction was performed on 16 isolates from Patient 
1 and 16 isolates from Patient 2 (Figure 1; Table 2), as previ-
ously described [9], with the addition of a bead beating step. 
The total DNA concentration was determined using the Qubit 
high-sensitivity assay kit (Thermofisher) and a sequencing li-
brary was prepared from 50  ng of DNA using the Nextera 
Library Preparation kit (Illumina). The post-PCR clean-up was 
carried out using Ampure XP beads (Beckman). The library 
size was validated using the Agilent 2200 TapeStation with 
the Agilent D1000 ScreenTape System, and 150 bp paired-end 
reads were sequenced on the Illumina NextSeq 550 system. The 
raw sequencing reads have been deposited on the European 
Nucleotide Archive (Study Accession PRJEB28875), as have 2 
assemblies used as de novo references (see below).
Sequence Data Analysis
Initial VNTR typing, carried out as described previously [9, 10], 
suggested the possibility of mixed infections, based on results 
intermediate between VNTR I  and the closely related VNTR 
I* profile (differing at 1 locus). A  preliminary mapping of all 
isolates to the standard M. abscessus strain ATCC 19977 chro-
mosome (NCBI Accession: CU458896.1) showed that the mean 
coverage at 10X was ~91%, contrasted with >99% for a represen-
tative set of VNTR II isolates from another patient sequenced 
with the same protocol (not shown). In order to ensure we cap-
tured as much genetic diversity as possible, we therefore adopted 
a hybrid de novo and mapping approach. We selected the first 
isolate (temporally) for each patient and performed de novo as-
sembly with SPAdes v3.10.0 with the --careful switch and, oth-
erwise, default parameters [11]. After removing contigs with 
<10 000 bases to exclude small, mobile, genetic elements, this 
first de novo assembly was used as a new reference to map raw 
reads from other isolates using bwa mem v0.7.12 with default 
parameters [12]. This produced de novo references for Patient 
1 and Patient 2, containing 5.17 Mb and 5.28 Mb, respectively 
(Table 1). Contigs were reordered against the M. abscessus ATCC 
19977 chromosome using Mauve v2.4.0 (2015-02-25) [13].
Variant Identification and Clustering Analysis
In brief, the mapping file was sorted and indexed using picard 
v1.130; then, Genome Analysis Toolkit v3.30 was used to create 
a combined variant call format file for each patient. Each po-
sition required a mapping depth >30 in all samples from a pa-
tient to be included in the downstream analysis. We manually 
inspected the “self-mapping” of the reads from the first tem-
poral sample to its own de novo assembly using Integrative 
Genomics Viewer v2.4.10 [14] to identify small regions where 
the mapping was problematic. We removed SNVs within iso-
lated regions where the self-mapping had unexpected peaks 
in coverage (Patient 1: contigs 12 [12  575-13  519 bp] and 19 
[96 916–97 032 bp]; Patient 2: contig 17 [12 718-12 770 bp]), 
as well as SNVs where the reference allele fraction from the 
self-mapping reads was <5%.
As noted by Bryant et  al [5], patterns of linkage of variants 
in M. abscessus can be suggestive of the existence of subpopula-
tions. We aimed to establish a conservative lower bound for the 
number of clonal subpopulations within a patient, inferring their 
Table 1. Summary Statistics for the De novo Reference Genomes of the 
2 Patients
 Patient 1 Patient 2
Total bases 5 172 759 5 275 491
Mean depth of coverage 25.3X 74.1X
Number of contigs 28 46
References were assembled for the first temporal sample from each patient (patient_1_S1 
and patient_2_S1; see Methods).
Table 2. Patient Clinical Data
Patient M. abscessus Subspecies Sex CF Genotype Date of Last Smear-positive Sample Date of Last M. abscessus Isolate
Patient 1 abscessus Female F508del/F508del −166 days +56 days
Patient 2 abscessus Male F508del/W1282X −81 days +59 days
Dates are relative to the patient’s day of transplant. 
Abbreviations: CF, cystic fibrosis; M. abscessus, Mycobacterium abscessus.
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existence from the linkage patterns of variant frequencies across 
all samples. Patterns of linkage disequilibrium can also occur, 
due to recombination; therefore, we attempted to remove local 
recombination in our analysis. Using the SNVs obtained via the 
mapping and filtering methods described above, we hierarchi-
cally clustered SNVs using Ward’s minimum variance criterion 
[15], applied to Euclidean distances between allele frequencies, 
with a dissimilarity threshold of 1 to define clusters. We removed 
clusters containing <4 SNVs. We also removed putative local 
recombination regions by removing clusters where the SNVs 
were distributed within a total range <100 000 bp (~2% of the 
M. abscessus genome).
In general, the inference of haplotype frequencies using variant 
frequencies from short sequencing reads for a microbial popu-
lation undergoing recombination is a complex problem [16]. 
However, as we are not attempting to comment on abundances 
of subpopulations, but only on their presence, we did not need to 
infer haplotype frequencies. Observing n distinct clusters of vari-
ants within a patient over time (ie, allele frequencies that covary 
in step with each other) means that there must be at least n bac-
terial haplotypes producing these patterns within the population. 
This fact holds even when recombination is present. Therefore, 
observing distinct clusters of linked variants tells us that distinct 
subpopulations of M. abscessus exist within individual samples.
RESULTS
Individuals Harbor Extensive Variation
We observed multiple positions in the M.  abscessus genome, 
which varied between different isolates within a patient over 
time (total variable positions used for clustering across all iso-
lates: Patient 1, 54 positions; Patient 2, 64 positions), although the 
isolates remained highly similar, on average, and were clearly the 
same infecting strain (mean inter-isolate SNV distances: Patient 1, 
2.07 +/- 0.92 SNVs; Patient 2, 1.96 +/- 1.81 SNVs). Subsets of these 
SNVs showed patterns of linkage across the M. abscessus genome 
(Figure 2A). Similar, clustered patterns of linked SNVs could also 
arise due to recombination, but clustered SNVs were widely spread 
across the genome, suggesting the presence of multiple subclones. 
Even if recombination were present, leading to mixtures of clus-
ters (ie, different haplotypes), then the observed abundance pat-
terns still required multiple subclones. A  neighbor-joining tree 
produced from the distances between isolates, based on these 
allele frequencies, also suggested multiple subclones (Figure 2B).
Figure 2. Linkage patterns of SNVs across samples suggest the presence of closely related subpopulations within patients. A and B, SNVs were grouped into clusters 
(colors) using an unsupervised clustering technique, showing clear patterns of abundance across samples (see Methods). The genome position was inferred by ordering de 
novo contigs against the Mycobacterium abscessus ATCC 19977 reference genome. C and D, The midpoint-rooted neighbor-joining trees are based on Euclidean distances 
between samples, using these clustered SNVs to show this variation within patients over time (numbers) and body sites (colors). Abbreviations: BAL, bronchoalveolar lavage; 
SNV, single-nucleotide variants. 
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Within-patient Variation Includes Antimicrobial Resistance Mutations
Macrolide resistance in M.  abscessus is driven by mutations 
at established positions in the rrl gene. Both patients received 
macrolides almost continuously throughout the 6 months prior 
to their transplants (Figure 1). While initial isolates taken ear-
lier in treatment were susceptible, we observed that resistance 
alleles at these positions (C/G) increased in abundance over 
time (Figure 3). Notably, all sputum isolates from Patient 1 
showed a susceptible allele at position 2059, whereas isolates 
from the pleural fluid and clamshell incision wound swabs 
carried a resistance allele (A2059C; Figure 3A). There was also 
substantial variation within sets of isolates taken on the same 
day. For example, 3 isolates from different lymph node samples 
taken on the day of transplant for Patient 2 showed completely 
different macrolide resistance profiles, most strikingly at po-
sition 2058 (Figure 3B). These positions were not among the 
SNVs clustered into subpopulation structure clusters in Patient 
2, but rrl 2059 was part of cluster 1.D in Patient 1, demonstrat-
ing that these resistance alleles can arise spontaneously, but also 
persist as linked to the genetic background.
We also observed variable positions in the rrs gene in both 
patients (Figure 4). The rrs gene codes for 16S ribosomal RNA 
(rRNA) and is often a site of the emergence of aminoglyco-
side resistance (eg, to amikacin), particularly in the last few 
100 bp of the gene, where the secondary structure of the rRNA 
can be affected by multiple mutations [17]. The de novo ref-
erence assembly for the gene in both patients was identical to 
the previously characterized sequence from amikacin-resistant 
M. abscessus [17, 18], which was consistent with the measured 
AMR phenotype of the first sputum sample in Patient 2, but not 
Patient 1 (Table 3). Subsequently, an isolate from the lung tissue 
of Patient 1, taken on the day of transplant, had a different al-
lele at position 1174 (C→T; Figure 4) and was partially resistant 
when phenotyped (Table 3), suggesting this mutation may have 
been involved in this resistance. In Patient 2, we observed both 
A and G at position 1374, corresponding to the A1400G muta-
tion, which confers high-level amikacin resistance in M. tuber-
culosis [19]. The G allele was dominant by the end of treatment, 
suggesting that it may have conferred higher resistance and/or 
been an important compensatory mutation.
Other sites also showed high levels of variation in both 
patients. After sorting SNVs by the standard deviation of 
the reference allele fraction across isolates (Supplementary 
Dataset 1), the most highly variable position in Patient 1 was 
Figure 3. Variants in the rrl gene (23S rRNA) arose during treatment and were present in isolates from concurrent samples. Relative allele fractions at these positions show 
that, although the initial sputum isolate was susceptible for both patients, resistance appeared to develop during treatment. Samples are ordered by time, with boxes indicat-
ing samples taken on the same day. Samples taken on the day of transplant are shown in bold text. Here, following the usual convention for the rrl gene, we use Escherichia 
coli numbering. Positions 2058 and 2059 in E. coli correspond to 2269 and 2270 in Mycobacterium abscessus. Abbreviations: BAL, bronchoalveolar lavage; CW, chest wound; 
DSW, drain site swab; LN, lymph node; LT, lung tissue; PF, pleural fluid; S, sputum.
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in the putative ferric uptake regulator FurB (MAB_1678c). 
This variant was present at high abundance in samples taken 
49  days after transplant, with the reference allele fraction 
only present at <2% in 1 pleural fluid sample (Supplementary 
Dataset 1). Ferric uptake regulation has been associated with 
the virulence of pathogenic mycobacteria; in mycobacterial 
infections, the host response deprives the bacteria of iron to 
prevent replication [20]. Iron is important for growth and vir-
ulence in M. abscessus [21], with gallium used as a treatment 
because of its ability to inhibit iron-dependent enzymes [22]. 
The most variable position in Patient 2 was within a putative 
linoleoyl-coenzyme A (CoA) desaturase (MAB_2148), and the 
second most highly variable position in Patient 2 was within 
the cell division control protein 48 (MAB_0347). Population 
heterogeneity via asymmetric cell division has been suggested 
as a factor facilitating the survival of M.  tuberculosis across 
host physiological niches [23], and the control of cell division 
is probably similarly important in the survival of M. absces-
sus across body sites. Although at different positions, both 
patients had a variable position within erm(41) (MAB_2297), 
which confers inducible resistance to macrolides [24].
Sputum Samples Do Not Reflect Overall Within-patient Diversity
The first sample from each patient was from sputum. The fre-
quencies of the reference alleles were significantly associated with 
body sites in Patient 2 (Kruskal-Wallis rank-sum test, P < .001), 
but not in Patient 1 (Kruskal-Wallis rank-sum test, P  =  .13). 
Reference allele frequencies were significantly higher in subse-
quent sputum isolates, compared to non-sputum isolates, for the 
majority of SNVs in both patients (Patient 1: 51/54 SNVs, with 
P  <  .05 after Benjamini-Hochberg correction; Patient 2: 61/64 
SNVs, with P <  .05 after Benjamini-Hochberg correction), sug-
gesting that sputum isolates tended to be more similar to the in-
itial sputum isolate used as a reference, even for Patient 1, where 
Figure 4. Variants in the rrs (16S rRNA) gene over the course of treatment. Patient 1: position 1174. Patient 2: position 1374, previously associated with amikacin resist-
ance (see text). The numbering is relative to ATCC 19977 reference. Abbreviations: BAL, bronchoalveolar lavage; CW, chest wound; DSW, drain site swab; LN, lymph node; 
LT, lung tissue; PF, pleural fluid; S, sputum. 
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3/3 subsequent sputum isolates were posttransplant (immuno-
suppressed). This also suggests that non-sputum isolates harbored 
additional diversity that was not well sampled using sputum.
DISCUSSION
In this retrospective study, we sought to establish the extent of 
within-patient variability of M. abscessus in 2 patients who de-
veloped severe complications following lung transplants as part 
of treatment for CF. We used WGS to characterize this varia-
bility in isolates from longitudinal clinical samples, and were 
able to reveal patterns of linkage of SNVs that were consistent 
with the presence of multiple subpopulations within patients.
Isolates from the same patient were similar—for example, all 
within-patient inter-isolate distances were within the threshold 
of 25 SNVs that was previously suggested for inferring poten-
tial transmission events [25] and, while mixed populations 
could theoretically lead to different transmission inferences, 
the between-patient variation was significantly larger—but this 
does not mean that the variation is not clinically significant. 
We have demonstrated that within-patient variation can be bi-
ologically and clinically important. Notably, we observed that 
variation at rrl 2058/2059, associated with macrolide resistance, 
developed over the course of treatment. We observed exten-
sive variation in isolates from Patient 2 prior to and on the day 
of transplant (ie, before the patient was immunosuppressed). 
Table 3. Routine Microbiology Data About Isolates
Sample Body Site Date Isolated Colony Morphotype VNTR Profile Phenotypic Susceptibility
patient_1_S1 Sputum -166 days Rough I Amikacin-S; Cipro-R; Clarithromycin-R;  
Doxycycline-R; Augmentin-R
patient_1_S2 Lung tissue 0 days Rough I Amikacin-PR; Cipro-R; Clarithromycin-R;  
Doxycycline-R; Linezolid-R; Co-trem-R;  
Cefotaxime-R
patient_1_S3 Sputum 10 days Smooth I n/a
patient_1_S4 Sputum 15 days Rough I n/a
patient_1_S5 Pleural fluid 21 days Smooth I n/a
patient_1_S6 Pleural fluid 38 days Rough I* n/a
patient_1_S7 Pleural fluid 38 days Rough I* n/a
patient_1_S8 Pleural fluid 40 days Smooth I* n/a
patient_1_S9 BAL 42 days Smooth I* n/a
patient_1_S10 Pleural fluid 49 days Smooth I* n/a
patient_1_S11 Pleural fluid 49 days Smooth I* n/a
patient_1_S12 Pleural fluid 49 days Smooth I* n/a
patient_1_S13 Chest wound swab 49 days Smooth I / I* n/a
patient_1_S14 Chest wound swab 49 days Smooth I n/a
patient_1_S15 Sputum 51 days Smooth I / I * n/a
patient_1_S16 Chest wound swab 56 days Rough I n/a
patient_2_S1 Sputum −121 days Rough n/a Amikacin-R; Cipro-R; Clarithromycin-R;  
Doxycycline-R; Linezolid-R;  
Co-trem-R; Cefotaxime-R
patient_2_S2 Sputum −81 days Smooth I n/a
patient_2_S3 Lymph node tissue 0 days Rough I n/a
patient_2_S4 Lymph node tissue 0 days Smooth n/a n/a
patient_2_S5 Lymph node tissue 0 days Rough I n/a
patient_2_S6 Lung tissue 0 days n/a I n/a
patient_2_S7 Sputum 14 days Smooth n/a n/a
patient_2_S8 BAL 27 days Smooth I n/a
patient_2_S9 Pleural fluid 33 days Smooth I n/a
patient_2_S10 BAL 41 days Smooth I / I* n/a
patient_2_S11 Pleural fluid 42 days Smooth I n/a
patient_2_S12 Pleural fluid 42 days Smooth I Amikacin-R; Ciprofloxacin-R;  
Clarithromycin-R; Doxycycline-R;  
Linezolid-R; Co-trimoxazole-R;  
Cefoxitin-R; Tobramycin-R;  
Moxyfloxacin-R
patient_2_S13 Drain site swab 49 days Smooth n/a n/a
patient_2_S14 Pleural fluid 50 days Smooth n/a n/a
patient_2_S15 Pleural fluid 58 days Smooth I n/a
patient_2_S16 Pleural fluid 59 days Smooth n/a n/a
Dates are relative to the date of transplant for each patient. An asterisk (*) indicates that the VNTR profile differed at 1 locus. Phenotypic susceptibility was available for a minority of isolates. 
Abbreviations: BAL, bronchoalveolar lavage; n/a, data not available; -PR, partially resistant; -R, resistant; -S, susceptible; VNTR, variable nucleotide tandem repeat.
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Isolates from Patient 1 prior to and on the day of transplant 
displayed no variation at these positions, so presumably, the 
phenotypic macrolide resistance reported in these samples at 
this time was due entirely to the inducible resistance conferred 
by erm(41). Nonetheless, rrl 2058/2059 variants were present 
in later isolates, suggesting that macrolide use still has a ther-
apeutic impact, even in the presence of a functional erm(41) 
gene, and drives the selection of high-level macrolide resistance. 
We also observed variation in the rrs gene—another source of 
resistance to antibiotics which target ribosomal function, such 
as amikacin—as both previously recorded and novel positions, 
including an allele that rose in dominance over the course of 
treatment in Patient 2 (Figure 4).
When resistance to antibiotics is driven by point mutations at 
single positions, natural mutation rates will lead to the repeated 
presence of naturally occurring, resistant cells. Conservatively, 
taking values from the more slow-growing and non-recom-
bining M. tuberculosis, a mutation rate of ~8 × 10-9 mutations 
per site per month [26] and a typical extracellular population 
of ~109 cells [27] clearly means that, during treatment, a typ-
ical within-patient population will repeatedly give rise to cells 
with the rrl 2058 mutation (for example). Typically, such muta-
tions have fitness costs, so remain at a low frequency, but in 
the presence of antibiotics, they rapidly achieve dominance. In 
M.  tuberculosis, combination therapy is specifically designed 
to combat this selection of resistance. The strong resistance se-
lection effect we observed for macrolides in M. abscessus high-
lights the weakness of current treatment regimens: particularly, 
the lack of good companion medications.
Based on this data, we would question how useful the phe-
notypic testing of isolates recovered from a limited number of 
sputum samples is for guiding antimicrobial therapy, as this 
strategy is unlikely to capture the diversity present in the full 
sample. Similarly, even though WGS is clearly a valuable tool, 
it may also fail to capture an accurate AMR profile if restricted 
to the analysis of sputum isolates. Previous studies on M. tuber-
culosis have shown that mycobacterial culture reduces the di-
versity recovered from sputum samples [28, 29]. It is, therefore, 
possible that the diversity found across different sample sites in 
this study may have been present in sputum samples, but was 
lost in the culture step. For M. tuberculosis, direct sequencing 
from sputum samples using capture-based enrichment meth-
ods has been shown to recover sample diversity not present in 
liquid culture [30]. By extension, it is possible that WGS, at a 
high depth, applied directly to sputum samples, could identify 
the variants detected between sample sites.
We observed highly variable positions in genes with direct rel-
evance for the survival of M. abscessus across different physiolog-
ical niches, such as the regulation of ferric uptake (MAB_1678c) 
and the control of cell division (MAB_0347). In a chronic infec-
tion, mycobacteria must cope with considerable host stresses, 
including iron starvation, which enables the persistence of 
M. tuberculosis in granulomas [31]. Phenotypic diversity due to 
expression can also occur: the colony morphotype (smooth or 
rough) has previously been linked to the phenotype, although 
both morphotypes appear to be capable of aggregation and intra-
cellular survival [32]. Further diversity may come from the sub-
populations harbored at different locations within the patient’s 
lungs. Regional selective pressures within the lungs have been 
shown to drive the diversification of Pseudomonas aeruginosa, 
another chronic CF pathogen, and we would expect similar dy-
namics for M. abscessus. In particular, different body regions may 
have different antibiotic antibiotic concentrations. It has been re-
cently shown for M.  tuberculosis that antibiotic concentrations 
vary across biopsy sites in cavities and that this variation is as-
sociated with different minimum inhibitory concentrations and 
resistance-associated variants [7]. It seems highly plausible that 
similar effects exist in M. abscessus infections, and this is an im-
portant area for further research.
Our findings suggest that the wider diversity present within 
patients chronically infected with M. abscessus is not well sam-
pled with sputum, and that the body site influences the subpop-
ulation structure. More widespread sampling of multiple body 
sites would provide a more accurate picture of the AMR pro-
file of M. abscessus in a patient, and may be necessary to guide 
targeted antimicrobial therapy prior to a transplant. However, 
in practical terms, this would mean taking biopsies, which car-
ries a significant clinical risk and would probably be unfeasible 
in patients awaiting transplants. An alternative solution to im-
prove patient management before a transplant might rely on 
deep-sequencing of multiple sputum samples. Such a strategy 
might capture a sufficient fraction of the total within-patient di-
versity to provide accurate information about the presence of 
minor variants: in particular, those conferring AMR.
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